CHRFAM7A Antibody

What is CHRFAM7A and why is it significant in human biology?

CHRFAM7A is a human-specific fusion gene that acts as a negative regulator of the α7 nicotinic acetylcholine receptor (α7nAChR). This gene is uniquely human, resulting from a series of recombination events including duplications, deletion, and inversion in humanoids . The significance of CHRFAM7A lies in its role in modulating α7nAChR function, which is involved in cognition, neuroinflammation, and immune responses. Being human-specific, CHRFAM7A may account for the translational gap observed when testing α7nAChR-targeting drugs in animal models versus human clinical trials .

CHRFAM7A exhibits different copy number variations (CNV) in the human genome with high frequency, resulting in three distinct alleles:

• The ancestral allele lacking the fusion gene (0 copy)

• The fusion gene in direct orientation (CHRFAM7A)

• The fusion gene in inverted orientation characterized by a 2 bp deletion in exon 6 (CHRFAM7AΔ2bp)

Population frequency data indicate that non-carriers of the functional direct allele comprise approximately 25% of the human population, while carriers of the direct CHRFAM7A functional allele represent about 75% of the population .

How does CHRFAM7A protein (dupα7) interact with α7nAChR?

CHRFAM7A encodes a protein called dupα7, which can assemble with α7 subunits and form heteromeric α7-nAChR/dupα7 receptors with altered pharmacological properties compared to homopentameric α7-nAChR . When incorporated into the receptor, dupα7 downregulates the activity of α7-nAChR mainly due to a reduction in the number of acetylcholine binding sites . This mechanism results in decreased calcium influx and a prolonged channel closed state , shifting calcium dynamics within the cell.

The 412-amino acid dupα7 polypeptide preserves many features of nAChR subunits, including four transmembrane domains (M1-M4) and the long intracellular loop between M3 and M4 . This structural similarity allows it to incorporate into α7nAChR pentamers based on gene dosage, functioning as a dominant negative modulator .

What criteria should researchers consider when selecting CHRFAM7A antibodies?

When selecting CHRFAM7A antibodies, researchers should consider:

• Epitope specificity: Since CHRFAM7A shares significant sequence homology with CHRNA7, it's crucial to select antibodies that specifically target unique regions of CHRFAM7A. Look for antibodies raised against the N-terminal region of CHRFAM7A, which differs from CHRNA7 .

• Validated applications: Verify that the antibody has been validated for your specific applications (Western blot, immunohistochemistry, immunofluorescence, etc.) in peer-reviewed publications .

• Species reactivity: Confirm the antibody's reactivity with human samples, as CHRFAM7A is human-specific. Some antibodies may cross-react with mouse and rat samples, but this would detect only CHRNA7 in those species .

• Clonality: Consider whether a monoclonal or polyclonal antibody better suits your experimental needs. Polyclonal antibodies may offer higher sensitivity but potentially lower specificity .

• Immunogen information: Review the specific peptide sequence or protein region used as the immunogen to ensure it uniquely identifies CHRFAM7A rather than CHRNA7 .

How can researchers validate CHRFAM7A antibody specificity?

To validate CHRFAM7A antibody specificity, researchers should implement multiple approaches:

• Genetic controls: Use cells with known CHRFAM7A genotypes (0 copy, 1 copy, etc.) as positive and negative controls. iPSC lines with characterized CHRFAM7A status are ideal for this purpose .

• Overexpression validation: Test the antibody in a system overexpressing CHRFAM7A via transfection or lentiviral delivery, comparing signal to empty vector controls .

• Knockdown validation: Use siRNA or CRISPR-Cas9 to reduce CHRFAM7A expression and confirm corresponding reduction in antibody signal .

• Western blot molecular weight verification: CHRFAM7A protein (dupα7) has an expected molecular weight of approximately 46 kDa, which should be distinguishable from full-length CHRNA7 .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm signal elimination in specific binding.

• Cross-reactivity assessment: Test the antibody in rodent samples (which lack CHRFAM7A) to check for cross-reactivity with CHRNA7 .

What are the optimal methods for detecting CHRFAM7A genotype and copy number variation?

Multiple complementary approaches can be used to detect CHRFAM7A genotype and copy number variation:

• TaqMan Copy Number Assay: This is the most widely used method for CHRFAM7A CNV determination. Design primers and probes to detect the breakpoint sequence specific to CHRFAM7A. Use the RNaseP gene as a reference for normalization .

  Protocol outline:

  • Perform duplex real-time PCR with FAM-labeled CHRFAM7A assay and VIC-labeled RNaseP reference

  • Run each sample in quadruplicate using 10 ng DNA per reaction

  • Determine threshold cycle (Ct) values for CHRFAM7A and RNaseP

  • Calculate relative quantity using the ΔΔCt method

• Breakpoint-specific PCR: For determining both copy number and orientation:

  • Design primers that span the unique breakpoint regions

  • Long amplification of the CHRFAM7A intron (from exon A to exon 5) using high-fidelity polymerase

  • Run PCR products on agarose gel to determine presence/absence and amplicon size

• Whole Genome Sequencing: For comprehensive analysis, WGS can determine exact copy number and identify potential variants in CHRFAM7A .

• Capillary sequencing: To determine the orientation of CHRFAM7A alleles (direct vs. inverted) .

What are effective protocols for immunodetection of CHRFAM7A protein?

For effective immunodetection of CHRFAM7A protein:

• Western Blot Protocol:

  • Sample preparation: Use RIPA buffer with protease inhibitors for total protein extraction

  • Protein separation: Run 20-40 μg protein on 10% SDS-PAGE gel

  • Transfer: Use PVDF membrane with wet transfer (recommended over nitrocellulose due to protein hydrophobicity)

  • Blocking: 5% non-fat milk in TBST for 1 hour at room temperature

  • Primary antibody: Anti-CHRFAM7A (dilution 1:200-1:1000 based on antibody specifics) overnight at 4°C

  • Secondary antibody: HRP-conjugated anti-rabbit IgG (1:5000)

  • Expected band: ~46 kDa for CHRFAM7A protein

• Immunofluorescence Protocol:

  • Fixation: 4% paraformaldehyde for 15 minutes

  • Permeabilization: 0.25% Triton X-100 for 10 minutes

  • Blocking: 5% normal goat serum in PBS for 1 hour

  • Primary antibody: Anti-CHRFAM7A antibody (1:200-1:3000) overnight at 4°C

  • Secondary antibody: AlexaFluor 488/594 conjugated antibody (1:400) for 2 hours at room temperature

  • Counterstain: DAPI for nuclear visualization

  • Imaging: Confocal microscopy for subcellular localization analysis

• Flow Cytometry for Cell Surface Expression:

  • Cell preparation: Non-permeabilized cells for surface staining

  • Blocking: 2% BSA in PBS for 30 minutes

  • Primary antibody: Anti-CHRFAM7A antibody targeting extracellular domain

  • Secondary antibody: Fluorophore-conjugated secondary antibody

  • Controls: Include isotype control and CHRFAM7A-negative cells

How can researchers effectively study CHRFAM7A modulation of α7nAChR function?

To study CHRFAM7A modulation of α7nAChR function:

• Electrophysiology Approaches:

  • Patch-clamp recordings in cells with defined CHRFAM7A genotypes

  • Compare α7nAChR currents between CHRFAM7A-null, native expression, and overexpression systems

  • Assess PNU-modulated desensitization of α7nAChR currents as a function of CHRFAM7A dosage

  • Measure channel open probability and current amplitude in response to agonists

• Calcium Imaging:

  • Use fluorescent calcium indicators (Fluo-4, Fura-2) to measure intracellular calcium dynamics

  • Compare responses to α7nAChR agonists between different CHRFAM7A genotypes

  • Analyze both amplitude and kinetics of calcium signals, as CHRFAM7A shifts Ca²⁺ dynamics from extracellular space to endoplasmic reticulum

• Binding Assays:

  • Use radioligand binding assays with [¹²⁵I]-α-bungarotoxin to quantify binding site availability

  • Compare binding characteristics (Kd, Bmax) between CHRFAM7A-positive and negative samples

  • Assess competitive binding with various α7nAChR ligands to determine if CHRFAM7A alters pharmacological profiles

• Protein-Protein Interaction Studies:

  • Co-immunoprecipitation of α7nAChR and CHRFAM7A to confirm direct interaction

  • Proximity ligation assays to visualize interactions in situ

  • FRET/BRET approaches to study real-time interactions in live cells

What experimental models are most suitable for studying CHRFAM7A in the context of neurological disorders?

The most suitable experimental models for studying CHRFAM7A in neurological disorders include:

• Human iPSC-Derived Neuronal Models:

  • iPSC lines with characterized CHRFAM7A genotypes (0 copy, 1 copy direct, etc.)

  • Differentiation into specific neuronal subtypes (interneurons, glutamatergic neurons)

  • Genome editing to express or delete CHRFAM7A in isogenic backgrounds

  • 3D organoid models to recapitulate more complex neural environments

• CHRFAM7A Transgenic Mouse Models:

  • Transgenic mice expressing human CHRFAM7A under tissue-specific promoters

  • Assessment of behavioral phenotypes, neuroinflammation, and neurodegeneration

  • Challenge models (e.g., Aβ exposure, inflammatory stimuli) to evaluate CHRFAM7A's role in pathology

  • Combined models with other neurological disease mutations

• Ex Vivo Human Brain Tissue:

  • Postmortem brain samples with genotyped CHRFAM7A status

  • Regional distribution analysis of CHRFAM7A expression in neurological disorders

  • Correlation between CHRFAM7A expression and neuropathological markers

• Pharmacological Studies:

  • Testing α7nAChR modulators in systems with defined CHRFAM7A status

  • Evaluating dose-response relationships in CHRFAM7A-positive versus negative models

  • Pharmacogenetic studies in clinical populations stratified by CHRFAM7A genotype

How should researchers account for CHRFAM7A copy number variation when interpreting experimental results?

Accounting for CHRFAM7A copy number variation requires several strategic approaches:

• Comprehensive Genotyping:

  • Determine both copy number and orientation (direct vs. inverted) for all samples

  • Create experimental groups based on genotype: 0 copy, 1 copy direct, 1 copy inverted, etc.

  • Remember that only the direct orientation is translated into functional protein

• Population Stratification:

  • Consider that approximately 75% of the human population carries the direct, functional CHRFAM7A allele, while 25% are non-carriers

  • Be aware of potential differences in allele frequencies across racial and ethnic groups

• Statistical Analysis:

  • Treat CHRFAM7A status as an independent variable in statistical models

  • Consider interactions between CHRFAM7A status and other variables (age, sex, disease status)

  • For clinical studies, use CHRFAM7A as a covariate or stratification factor

• Dose-Response Relationships:

  • Analyze data for dose-dependent effects of CHRFAM7A (0, 1, 2 copies)

  • The effect on α7nAChR function and phenotypic outcomes often scales with CHRFAM7A copy number

What are common pitfalls in CHRFAM7A research and how can they be addressed?

Common pitfalls in CHRFAM7A research include:

• Cross-Species Translation Issues:

  • Pitfall: Directly applying findings from animal models to humans without accounting for CHRFAM7A's absence in non-human species

  • Solution: Use humanized models (transgenic mice, human iPSCs) or explicitly acknowledge this limitation

• Antibody Cross-Reactivity:

  • Pitfall: Using antibodies that cannot distinguish between CHRFAM7A and CHRNA7

  • Solution: Validate antibody specificity using genetic controls and multiple detection methods

• Incomplete Genotyping:

  • Pitfall: Determining only copy number without orientation, leading to misclassification

  • Solution: Use comprehensive genotyping approaches that determine both copy number and orientation

• Sample Size Limitations:

  • Pitfall: Underpowered studies that fail to account for CHRFAM7A genetic diversity

  • Solution: Conduct power calculations based on expected allele frequencies and include CHRFAM7A status in study design

• Functional Assessment Challenges:

  • Pitfall: Attributing all observed effects to CHRFAM7A without mechanistic validation

  • Solution: Use isogenic models with CHRFAM7A as the only variable and perform rescue experiments

How does CHRFAM7A influence the response to Aβ in Alzheimer's disease models?

CHRFAM7A significantly impacts the neuronal response to Aβ through several mechanisms:

• Modulation of Aβ Uptake:

  • CHRFAM7A mitigates the dose response of Aβ 1-42 uptake, suggesting a protective effect beyond physiological concentrations

  • In iPSC models, CHRFAM7A expression reduces Aβ 1-42 internalization, potentially limiting direct neurotoxicity

• Altered Inflammatory Signaling:

  • In the presence of CHRFAM7A, Aβ 1-42 uptake activates neuronal interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) without activating the canonical inflammasome pathway

  • This creates a unique inflammatory signature that differs from the response in cells lacking CHRFAM7A

• Neuroprotective Effects:

  • Overexpression of CHRFAM7A in human iPSC-derived interneurons shows protective effects against Aβ-induced oxidative damage

  • This protection may result from altered calcium dynamics and subsequent changes in cellular stress response pathways

• Pharmacological Implications:

  • CHRFAM7A alters the response to α7nAChR-targeting drugs in the presence of Aβ

  • Drug screening should incorporate models harboring CHRFAM7A for more translational relevance

What role does CHRFAM7A play in neuroinflammation and the immune response?

CHRFAM7A shapes neuroinflammation and immune responses through multiple mechanisms:

• Calcium Signaling Modulation:

  • CHRFAM7A/α7nAChR functions as a hypomorphic receptor with mitigated Ca²⁺ influx and prolonged channel closed state

  • This shifts the Ca²⁺ reservoir from extracellular space to the endoplasmic reticulum, leading to distinct calcium dynamics

  • The calcium decoder small GTPase Rac1 is activated, reorganizing the actin cytoskeleton

• Hematopoietic Effects:

  • CHRFAM7A increases the hematopoietic stem cell (HSC) reservoir in bone marrow

  • It biases HSC differentiation toward the monocyte lineage over granulocytes

  • During systemic inflammatory response syndrome (SIRS), CHRFAM7A increases immune cell mobilization and myeloid cell differentiation

• Microglial Function:

  • In microglia, CHRFAM7A affects phagocytosis, motility, and tissue mechanosensation via actin cytoskeleton reorganization

  • This allows immune cells to invade previously immune restricted niches, potentially altering neuroinflammatory responses

• Cholinergic Anti-inflammatory Pathway:

  • CHRFAM7A dominant-negatively regulates α7nAChR, a key effector of the cholinergic anti-inflammatory pathway

  • This may prime macrophages for heightened pro-inflammatory responses at earlier stages of inflammation

  • The modification of this pathway may contribute to human-specific differences in inflammatory diseases

What experimental approaches can detect the interaction between CHRFAM7A and α7nAChR in native tissues?

To detect CHRFAM7A-α7nAChR interactions in native tissues:

• Proximity Ligation Assay (PLA):

  • Use antibodies specific to unique regions of CHRFAM7A and CHRNA7

  • Apply PLA in fixed tissue sections or primary cell cultures

  • Quantify interaction signals as puncta per cell or region

  • This approach allows visualization of protein interactions with subcellular resolution

• Co-immunoprecipitation from Native Tissues:

  • Prepare membrane fractions from brain or immune tissues

  • Immunoprecipitate with anti-CHRNA7 antibodies, followed by western blotting with CHRFAM7A-specific antibodies

  • Include appropriate controls (IgG, CHRFAM7A-null tissues)

  • Use mild detergents to preserve protein-protein interactions

• Mass Spectrometry-Based Approaches:

  • Immunopurify α7nAChR complexes from native tissues

  • Perform protein identification by LC-MS/MS

  • Quantify CHRFAM7A peptides relative to CHRNA7 peptides

  • Use crosslinking mass spectrometry to identify specific interaction interfaces

• Single-Molecule Imaging Techniques:

  • Label CHRFAM7A and CHRNA7 with distinct fluorophores using specific antibodies

  • Apply super-resolution microscopy (STORM, PALM) to visualize co-localization

  • Analyze receptor clustering and stoichiometry

  • Track dynamic interactions using live cell imaging if possible

How might CHRFAM7A genotyping influence clinical trial design for neurological disorders?

CHRFAM7A genotyping could significantly impact clinical trial design through:

• Patient Stratification:

  • Categorize participants based on CHRFAM7A genotype (non-carriers, 1 copy direct, etc.)

  • Analyze drug responses separately for each genotype group

  • This approach may uncover efficacy signals obscured in unstratified analyses

• Precision Medicine Approaches:

  • Develop different dosing strategies for different CHRFAM7A genotypes

  • Create CHRFAM7A genotype-specific inclusion criteria for trials of α7nAChR modulators

  • Design companion diagnostics for CHRFAM7A status to guide treatment selection

• Pharmacogenetic Modeling:

  • Include CHRFAM7A status as a variable in pharmacokinetic/pharmacodynamic models

  • Adjust for CHRFAM7A effects in statistical analyses of clinical outcomes

  • Develop algorithms that incorporate CHRFAM7A status for predicting treatment response

• Biomarker Development:

  • Correlate CHRFAM7A status with imaging, fluid, or electrophysiological biomarkers

  • Identify CHRFAM7A-specific disease signatures

  • Use these correlations to track disease progression and treatment effects

What are promising techniques for targeting CHRFAM7A or its interaction with α7nAChR therapeutically?

Promising therapeutic approaches targeting CHRFAM7A include:

• Allosteric Modulators:

  • Develop compounds that selectively modulate α7nAChR function in the presence of CHRFAM7A

  • Screen for molecules that reverse CHRFAM7A's dominant negative effects

  • Optimize compounds through structure-activity relationship studies in CHRFAM7A-expressing models

• RNA-Based Therapeutics:

  • Design antisense oligonucleotides or siRNAs targeting CHRFAM7A mRNA

  • Develop CHRFAM7A-specific guide RNAs for CRISPR-based approaches

  • Create splice-modulating therapies to alter CHRFAM7A expression patterns

• Interface-Targeting Peptides:

  • Design peptides that interfere with CHRFAM7A-α7nAChR protein interactions

  • Develop cell-penetrating peptides that modulate assembly of receptor complexes

  • Test these peptides in disease-relevant cellular and animal models

• Gene Therapy Approaches:

  • Viral vector-mediated delivery of engineered CHRFAM7A variants

  • CRISPR-based genome editing to modify CHRFAM7A expression or function

  • Cell-based therapies using engineered stem cells with optimized CHRFAM7A status